Clinical appraisal of tafluprost in the reduction of elevated intraocu
An elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which causes progressive blindess.
Tafluprost was recently launched onto the market to lower eye pressure. Some studies suggest it has greater pressure-lowering effect with fewer side effects than Xalatan. It also appears to protect the optic nerve, independent of it's ability to lower pressure. If these findings are true, then we will have another weapon in our arsenal against glaucoma.